Piramal Pharma will host institutional investor meetings in the United Kingdom on September 29 and 30, 2026. The company disclosed the schedule pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meetings are organized by Avendus Spark Institutional Equities and will be conducted in a physical format. Sessions will include both group discussions and one-on-one interactions with analysts and investors.

Meeting Schedule

Maneesh Sharma, Company Secretary and Compliance Officer, confirmed the schedule in a filing dated September 8, 2026. The company noted that dates are subject to change due to exigencies on the part of investors or the company.

Deutsche Bank AG has re-created a pledge over 98,400,000 equity shares of Piramal Pharma Limited , representing 7.39% of the issued and paid-up share capital on a fully diluted basis.

The disclosure was filed with the stock exchanges on August 26, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The re-pledge restores the total encumbrance held by the bank to 238,663,700 shares, or 17.93% of the total share capital.

Transaction Details

The borrower, CA Alchemy Investments, initially pledged 238,663,700 shares (17.93%) in favor of Deutsche Bank AG, Mumbai Branch, acting as the onshore security agent for lenders including Barclays Bank PLC and Nomura Singapore Limited. This initial pledge was disclosed on May 30, 2024.

On August 17, 2026, the bank released 98,400,000 shares (7.39%) to facilitate a 'Permitted Sale Transaction' as defined in the facility agreement dated February 22, 2024. Following this release, the borrower re-created the pledge over the same block of shares on August 24, 2026.

Security Structure

Deutsche Bank AG holds the pledge in its capacity as pledgee and does not hold any beneficial interest in the shares. The offshore security agent, Deutsche Bank AG, Singapore Branch, continues to hold security interest over all shares of the borrower held by its shareholders pursuant to a deed of fixed and floating charge dated March 11, 2024.

DBX Advisors LLC holds a nominal stake of 1,317 equity shares, aggregating to approximately 0.00% of the target company's shareholding as of the disclosure date.